Small Caps | LTR Pharma’s SPONTAN nasal spray achieves superior results in erectile dysfunction clinical study

LTR Pharma’s successful results from its pivotal bioequivalence clinical study have been featured in Small Caps, highlighting the positive market response to the announcement.

Journalist Colin Hay wrote:

” LTR Pharma (ASX: LTP) has come out of a trading halt with the announcement of successful results from a pivotal bioequivalence clinical study into a breakthrough treatment for erectile dysfunction (ED).

The company’s share price jumped by 37% after initial results from the study of LTR’s SPONTAN first-in-kind nasal spray treatment found it achieved rapid absorption and faster onset of action compared to well-known oral treatments.”

Click here to read the article.